Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer
| Autor: | Hiroyasu Yamashiro, Shinji Ozaki, Nao Morii, Takayoshi Kiba, Yoshimi Shitakubo, Misao Atsumi, Hirotoshi Takahashi, Fumi Masumoto |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Neutropenia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Trastuzumab Internal medicine medicine 030102 biochemistry & molecular biology business.industry Cancer Articles medicine.disease Surgery Supraclavicular lymph nodes Regimen medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis business Progressive disease Eribulin medicine.drug |
| Zdroj: | Molecular and clinical oncology. 4(1) |
| ISSN: | 2049-9450 |
| Popis: | There are limited studies reported that describe the efficacy of eribulin and trastuzumab in the treatment of recurrent breast cancer. The present study examined the therapeutic efficacy of eribulin and trastuzumab in the treatment of recurrent breast cancer. Between October 2011 and August 2013, 5 recurrent breast cancer patients who were treated with eribulin and trastuzumab were included in the study. The cancer stages in the 5 women who received this regimen were stage IIIB in 1 (20%) and stage IV in 4 (80%). The sites of recurrence were the lung in 3 patients, liver in 2, bone in 1, brain in 1, supraclavicular lymph nodes in 1, infraclavicular lymph nodes in 1 and mediastinal lymph nodes in 1. The median number of prior treatment regimens was 5 (range, 5–11). Complete response was achieved in 0 patients, 1 achieved partial response, 3 had stable disease, and 1 had progressive disease. The overall response rate was 20%, and the clinical benefit rate was 80%. Patients also reported grade 3/4 neutropenia (80.0%). However, hematological toxicity was reversible and manageable. The most common grade 3/4 nonhematological toxicities were fatigue (20.0%), peripheral neuropathy (20.0%) and appetite loss (20.0%). No patients withdrew from treatment, and favorable compliance was achieved in the study. The results indicated that eribulin and trastuzumab have the potential to be one of the drugs for treatment of recurrent breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|